Abstract
Increased submesothelial collagen deposition, loss of mesothelial cells and increased peritoneal vascularization of peritoneal membrane with vasculopathy leads to peritoneal fibrosis in a patient on long-term peritoneal dialysis (PD). This vascular proliferation within the peritoneum is associated with an increased expression of vascular endothelial growth factor (VEGF), which in turn leads to functional loss or deterioration of the peritoneal membrane over time. Vascular endothelial growth factor inhibitors may slow or even prevent vascular proliferation and subsequent loss of membrane function in peritoneal dialysis patient. We have observed the anti-VGEF effects of a tyrosine kinase inhibitor, sunitinib maleate, in a patient who was on this medication for renal cell carcinoma with extensive abdominal metastasis. The patient had also been on PD for 26 months at the time of the study. In this patient, the tyrosine kinase inhibitor helped to stabilize the abdominal metastasis as well as the thickness of the peritoneal membrane. The D/P creatinine ratio also remained stable. These observations suggest that this tyrosine kinase inhibitor may have prevented peritoneal membrane angiogenesis. We also observed that the patient did not have any further episode of peritonitis from gut-derived organisms, suggesting that stabilization of the intestinal metastasis prevented the transmural migration of bacteria from the gut, thereby preventing peritonitis.
References
Combet S, Van Landschoot M, Moulin P (2000) Vascular proliferation and enhanced expression of endothelial nitric oxide synthetase in human peritoneum exposed to long term peritoneal dialysis. J Am Soc Nephrol 11:717–728
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi:10.1056/NEJMoa065044
Rock EP, Goodman V, Jiang J, Mahjoor K, Verbois SL, Morse D, Dagher R, Justice R, Padzur R (2007) Food and drug administration drug approval summary: Sunitinib Maleate for treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 12:107–113. doi:10.1634/theoncologist.12-1-107
Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 7(25):884–896. doi:10.1200/JCO.2006.06.3602
Yoko Y, Masanobu M, Katsushige A, Tomoya N, Akira F, Yoshei M, Takashi H, Yoshiyuki O, Takehiko K, Shigeru (2004) TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int (66):1677–1685
Honda K, Nitta K, Horita S (1996) Morphologic changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72:171–176. doi:10.1159/000188837
Williams JD, Craig KJ, Topley N (2002) Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479
Zweers MM, Struijk DG, Smit W (2001) Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow up. J Lab Clin Med 137:125–132. doi:10.1067/mlc.2001.112235
Zweers MM DE, Waart DR, Smit W (1999) Growth factors VEGEF and TGF-beta 1 in peritoneal dialysis. J Lab Clin Med 134:124–132. doi:10.1016/S0022-2143(99)90116-6
Duman S, Ozbek SS, Gunay ES, Bozkurt D, Asci G, Sipahi S, Kircelli F, Ertilav M, Ozkahya M, Ok E (2007) What does peritoneal thickness in peritoneal dialysis patients tell us? Adv Perit Dial 23:28–33
Ahmad M, Shah H, Pliakogiannis T, Oreopoulos DG (2007) Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions. Int Urol Nephrol 39:299–312. doi:10.1007/s11255-006-9064-y
Krishnan A, Oreopoulos DG (2007) Peritoneal dialysis in congestive heart failure. Adv Perit Dial 23:82–89
Vas S (1983) Microbiologic aspects of chronic ambulatory peritoneal dialysis. Kidney Int 23:83–92. doi:10.1038/ki.1983.15
Stevenson JA, Jurado JL, Belli DD, Horton SJ (2006) Recurring enteric peritonitis associated with non-perforating colon carcinoma. Clin Nephrol 65(6):453–456
Schweinburg FB, Seligman AM, Fine J (1950) Transmural migration of intestinal bacteria. N Engl J Med 242:747–751
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tapiawala, S.N., Bargman, J.M., Oreopoulos, D.G. et al. Prolonged use of the tyrosine kinase inhibitor in a peritoneal dialysis patient with metastatic renal cell carcinoma: possible beneficial effects on peritoneal membrane and peritonitis rates. Int Urol Nephrol 41, 431–434 (2009). https://doi.org/10.1007/s11255-009-9545-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-009-9545-x